The effect on mortality of fluconazole or echinocandins treatment in internal medicine wards

PLoS ONE

Volumn 10, Issue 5, 2015, Pages

  De Rosa, Francesco G ^a   Corcione, Silvia ^a   Filippini, Claudia ^a   Raviolo, Stefania ^a   Fossati, Lucina ^a   Montrucchio, Chiara ^a   Aldieri, Chiara ^a   Petrolo, Alessia ^a   Cavallo, Rossana ^a   Di Perri, Giovanni ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; CASPOFUNGIN; FLUCONAZOLE; ECHINOCANDIN;

AGE; AGED; ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDEMIA; CAUSE OF DEATH; CENTRAL VENOUS CATHETER; COMORBIDITY; CONTROLLED STUDY; DEVICE REMOVAL; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; HUMAN; INCIDENCE; INTERNAL MEDICINE; LENGTH OF STAY; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEUROLOGIC DISEASE; NONHUMAN; PICHIA KUDRIAVZEVII; RETROSPECTIVE STUDY; SEPSIS; SURVIVAL RATE; THERAPY DELAY; TIME TO TREATMENT; WARD; HEALTH CARE FACILITY; MIDDLE AGED; MULTIVARIATE ANALYSIS; RISK FACTOR; STATISTICS AND NUMERICAL DATA;

CANDIDA;

AGED; CANDIDEMIA; ECHINOCANDINS; FEMALE; FLUCONAZOLE; HUMANS; INTERNAL MEDICINE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATIENTS' ROOMS; RISK FACTORS;

EID: 84929378285     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0125149     Document Type: Article

References (28)

1. Fortún J, Martín-Dávila P, Gómez-García de la Pedrosa E, Pintado V, Cobo J, Fresco G, et al. Emerging trends in candidemia: a higher incidence but a similar outcome. J Infect 2012; 65: 64-70 doi: 10.1016/j.jinf.2012.02.011 PMID: 22369861
2. Guimarães T, Nucci M, Mendonça JS, Martinez R, Brito LR, Silva N, et al. Epidemiology and predictors of a poor outcome in elderly patients with candidemia. Int J of Infect Dis 2012; 16: e442-e447. doi: 10.1016/j.ijid.2012.02.005 PMID: 22486857
3. Bassetti M, Merelli M, Righi E, Diaz-Martin A, Rosello EM Luzzati R, et al. Epidemiology, Species Distribution, Antifungal Susceptibility, and Outcome of Candidemia across Five Sites in Italy and Spain. J of Clinical Microbiol 2013; 51: 4167-4172 doi: 10.1128/JCM.01998-13 PMID: 24108614
4. Ha YE, Peck KR, Joo EJ, Kim SW, Jung SI, Chang HH, et al. Impact of first-line antifungal agents on the outcomes and costs of candidemia. Antimicrob Agents Chemother 2012; 56:3950-6 doi: 10.1128/AAC.06258-11 PMID: 22526315
5. Pfaller M, Neofytos D, Diekema D, Azie N, Meier-Kriesche HU, Quan SP, et al. Epidemiology and outcomes of candidemia in 3648 patients: data from the Prospective Antifungal Therapy [PATH Alliance] registry, 2004-2008. Diagn Microbiol Infect Dis 2012; 74: 323-31 doi: 10.1016/j.diagmicrobio.2012.10.003 PMID: 23102556
6. Bassetti M, Taramasso L, Nicco E, Molinari MP, Mussap M, Viscoli C. Epidemiology, species distribution, antifungal susceptibility and outcome of nosocomial candidemia in a tertiary care hospital in Italy. PLoS One 2011; 6:e24198 doi: 10.1371/journal.pone.0024198 PMID: 21935385
7. Lortholary O, Desnos-Ollivier M, Sitbon K, Fontanet A, Bretagne S, Dromer F, French Mycosis Study Group. Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: a prospective multicenter study involving 2,441 patients. Antimicrob Agents Chemother 2011; 55:532-8. doi: 10.1128/AAC.01128-10 PMID: 21078946
8. Leroy O, Gangneux JP, Montravers P, Mira JP, Gouin F, Sollet JP, et al. AmarCand Study Group. Epidemiology, management, and risk factors fordeath of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006). Crit. Care Med.2009; 37:1612-1618. doi: 10.1097/CCM.0b013e31819efac0 PMID: 19325476
9. Bassetti M, Molinari MP, Mussap M, Viscoli C, Righi E. Candidemia in internal medicine departments: the burden of a rising problem. Clin Microbiol Infect 2013; 19:281-284.
10. Tortorano AM, Prigitano A, Lazzarini C, Passera M, Deiana ML, Cavinato S, et al. A 1-year prospective survey of candidemia in Italy and changing epidemiology over one decade. Infection 2013; 41:655-62. doi: 10.1007/s15010-013-0455-6 PMID: 23559357
11. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: twenty second Informational Supplement M100-S22. Clinical and Laboratory Standards Institute (CLSI), 2012 Wayne, PA, USA.
12. De Rosa FG, Trecarichi EM, Montrucchio C, Losito AR, Raviolo S, Posteraro B, et al. Mortality in patients with early- or late-onset candidemia. J Antimicrob Chemother 2013; 68:927-35. doi: 10.1093/jac/dks480 PMID: 23236102
13. Garey KW, Rege M, Pai MP, Mingo DE, Suda KJ, Turpin RS, et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multiinstitutional study. Clin Infect Dis 2006; 43: 25-31. PMID: 16758414
14. Scudeller L, Viscoli C, Menichetti F, Del Bono V, Cristini F, Tascini C, et al. An Italian consensus for invasive candidiasis management (ITALIC). Infection 2014; 42:263-79. doi: 10.1007/s15010-013-0558-0 PMID: 24272916
15. Andes DR, Safdar N, Baddley JW, Playford G, Reboli AC, Rex JH, et al. Mycoses Study Group. Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. Clin Infect Dis 2012; 54:1110-22. doi: 10.1093/cid/cis021 PMID: 22412055
16. Colombo AL, Guimarães T, Sukienik T, Pasqualotto AC, Andreotti R, Queiroz-Telles F, et al. Prognostic factors and historical trends in the epidemiology of candidemia in critically ill patients: an analysis of five multicenter studies sequentially conducted over a 9-year period. Intensive Care Med 2014; 40:1489-98. doi: 10.1007/s00134-014-3400-y PMID: 25082359
17. Pappas PG, Kauffman CA, Andes D, Benjamin DK Jr, Calandra TF, Edwards JE Jr, et al. Infectious Diseases Society of America. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48:503-35. doi: 10.1086/596757 PMID: 19191635
18. Cornely OA, Bassetti M, Calandra T, Garbino J, Kullberg BJ, Lortholary O, et al ESCMID Fungal Infection Study Group. ESCMID∗ guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect 2012; 18:19-37. doi: 10.1111/1469-0691.12039 PMID: 23137135
19. Bassetti M, Righi E, Ansaldi F, Merelli M, Trucchi C, De Pascale G, et al. A multicenter study of septic shock due to candidemia: outcomes and predictors of mortality Intensive Care Med 2014; 40:839-845. doi: 10.1007/s00134-014-3310-z PMID: 24807083
20. Mora-Duarte J, Betts R, Rotstein C, Colombo AL, Thompson-Moya L, Smietana J, et al. Caspofungin Invasive Candidiasis Study Group. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002; 347:2020-9 PMID: 12490683
21. Reboli AC, Rotstein C, Pappas PG, Chapman SW, Kett DH, Kumar D, et al. Anidulafungin Study Group. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007; 356:2472-82 PMID: 17568028
22. Fernández-Ruiz M, Aguado JM, Almirante B, Lora-Pablos D, Padilla B, Puig-Asensio M, et al. CANDI-POP Project; GEIH-GEMICOMED (SEIMC); REIPI Initial use of echinocandins does not negatively influence outcome in C. parapsilosis bloodstream infection: a propensity score analysis. Clin Infect Dis. 2014; 58:1413-21. doi: 10.1093/cid/ciu158 PMID: 24642553
23. Macphail GL, Taylor GD, Buchanan-Chell M, Ross C, Wilson S, Kureishi A. Epidemiology, treatment and outcome of candidemia: a five-year review at three Canadian hospitals. Mycoses 2002; 45: 141-145. PMID: 12100528
24. Tortorano AM, Peman J, Bernhardt H, Klingspor L, Kibbler CC, Faure O, et al. ECMM Working Group on Candidaemia. Epidemiology of candidemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study. Eur J Clin Microbiol Infect Dis 2004; 23: 317-322. PMID: 15029512
25. Almirante B, Rodriguez D, Park BJ, Cuenca-Estrella M, Planes AM, Almela M, et al. Barcelona Candidemia Project Study Group. Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, Barcelona, Spain, from 2002 to 2003. J Clin Microbiol 2005; 43: 1829-1835. PMID: 15815004
26. Cisterna R, Ezpeleta G, Telleria O, Spanish Candidemia Surveillance Group. Nationwide sentinel surveillance of bloodstream Candida infections in 40 tertiary care hospitals in Spain. J Clin Microbiol 2010; 48: 4200-6. doi: 10.1128/JCM.00920-10 PMID: 20826636
27. Poikonen E, Lyytikainen O, Anttila VJ, Koivula I, Lumio J, Kotilainen P, et al. Secular trend in candidemia and the use of fluconazole in Finland, 2004-2007. BMC Infect Dis 2010; 10:312. doi: 10.1186/1471-2334-10-312 PMID: 21029444
28. Luzzati R, Amalfitano G, Lazzarini L, Soldani F, Bellino S, Solbiati M et al. Nosocomial candidemia in non-neutropenic patients at an Italian tertiary care hospital. Eur J Clin Microbiol Infect Dis 2000; 19: 602-7. PMID: 11014622